Ron Laufer
Senior Managing Director @ MedImmune Ventures
Gaithersburg, United States
Ron Laufer is a Series A investor at MedImmune Ventures in Gaithersburg focused on Medical and Therapeutics. Ron started his career as a physician and entrepreneur, before moving into venture capital. He was a co-founder of Lilly Ventures, the venture capital arm of Eli Lilly & Company, and later a managing director at Visium Asset Management, a healthcare-focused investment firm, before joining MedImmune Ventures in April of 2010.Ron receivedhis B.Sci., M.D. and M.P.H. from Hebrew University, and an M.B.A. from the Harvard Business School. He is currently an adjunct Professor of business administration at the Kelley Business School.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Ron Laufer invests in
Stages Ron Laufer invests in
Countries Ron Laufer invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (33%)
- Therapeutics 1 (33%)
- Biotechnology 1 (33%)
- Developer Platform 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Series C 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
G1 Therapeutics
|
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | $47M / Series C / May 11, 2016 | |
|
G1 Therapeutics
|
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | $33M / Series B / Feb 05, 2015 | |
|
G1 Therapeutics
|
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | Series A / Oct 16, 2013 |
Co-Investors
About MedImmune Ventures
MedImmune Ventures invests in early to late stage, public and private biotechnology companies.
MedImmune Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ron Laufer
Senior Managing Director
|
|||
Tyrell Rivers
Senior Associate
|
|||
|
Franklin H. Top
Vice President
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ron Laufer invest in?
Ron Laufer invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ron Laufer?
Public channels for Ron Laufer include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ron Laufer last invest?
The most recent investment recorded for Ron Laufer closed in May 2016. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
